Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
出版年份 2022 全文链接
标题
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
作者
关键词
Regorafenib, Avelumab, Biliary tract cancer, Immunotherapy, Cholangiocarcinoma
出版物
EUROPEAN JOURNAL OF CANCER
Volume 162, Issue -, Pages 161-169
出版商
Elsevier BV
发表日期
2022-01-06
DOI
10.1016/j.ejca.2021.11.012
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Angiogenesis in biliary tract cancer: targeting and therapeutic potential
- (2021) Margherita Rimini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.
- (2021) Shalini Makawita et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial – REACHIN
- (2020) A. Demols et al. ANNALS OF ONCOLOGY
- A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
- (2020) Richard D. Kim et al. CANCER
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
- (2020) Robert Montal et al. JOURNAL OF HEPATOLOGY
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
- (2020) Soomin Ahn et al. Scientific Reports
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
- (2019) Tanios S Bekaii-Saab et al. LANCET ONCOLOGY
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
- (2018) Brian W. Labadie et al. CLINICAL CANCER RESEARCH
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma
- (2016) Kulthida Vaeteewoottacharn et al. TUMOR BIOLOGY
- Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
- (2015) A. Moeini et al. CLINICAL CANCER RESEARCH
- Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma
- (2014) Hiroyuki Takahashi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
- (2013) Daniela Sia et al. GASTROENTEROLOGY
- Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
- (2011) Hiroaki Sugiyama et al. JOURNAL OF GASTROENTEROLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
- (2009) D Yoshikawa et al. BRITISH JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial
- (2007) Sarah Zohar et al. Contemporary Clinical Trials
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now